Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Norway-based biopharmaceutical company PCI Biotech has been awarded NOK10.85m in a BIA grant from The Research Council of Norway to the project ‘Immunological effects of photochemical internalization - local treatment of cancer with metastasis.”
Subscribe to our email newsletter
The project will be initiated in Q3 2011 and run for three years.
The grant will cover up to 35% of the project costs.
PCI Biotech is developing a novel light directed drug delivery system based on its patented photochemical internalization (PCI) technology.
PCI can enhance the delivery of all molecules taken into the cell by endocytosis, including most types of macromolecules, drugs carried by antibodies or nanoparticles, as well as some small molecule drugs.
The project goal is to document that the company’s PCI induces immunological mechanisms in cancer treatment, and to develop a treatment regime for optimal use of this mechanism.
The PCI method involves first injecting Amphinex and thereafter the therapeutic drug to be specifically delivered to the diseased cells.
When these are illuminated the cells’ endosomes are ruptured to allow successful intracellular delivery of the drug.